Any current/future new fundraising through debt or equity?

The company is currently undertaking a preferential allotment (equity fundraising) to acquire a patient service programs company. Due diligence and discussions regarding this acquisition are ongoing, with the announcement expected soon, possibly within the current quarter. The funds raised through the preferential allotment will be used primarily for this acquisition. For expanding the QDevices brand, capital is expected to come from existing revenue streams, not requiring additional capital raise. There is no explicit mention of new debt fundraising in the provided excerpts. The company focus

Any current/future capex/capital investment/strategic investment?

The company has invested approximately INR 15 to 20 crores as capex, primarily towards equipment for Patient Service Camps. Each representative carries machinery worth INR 15 to 17 lakhs. A significant capex has been brought in for the cancer model as part of new product efforts. The focus is on increasing the number of technicians and field staff with devices over the next six to eight months to meet high demand. Capital expenditures also support expansion in patient service programs and product business growth. The company is pursuing acquisitions in the patient services business; due dilige

Future growth expectations in sales/revenue/volumes?

The company aims to grow its patient service programs to INR 100 crores over the next three years, up from current INR 15-20 crores annually. Growth includes acquisition of a similar-sized company expected to double the patient services segment. Product business is targeted to grow at a steady rate of approximately 15% annually. Focus on expanding the number of field technicians and dietitians to meet growing demand in patient services. Online sales to increase gradually by expanding product portfolio beyond current limited range, focusing on wellness and fitness sectors. The company

Future growth expectations in earnings/operating earnings/profits/EPS?

The company focuses on achieving steady growth over the next 2-3 years rather than projecting long-term 5-year targets due to dynamic business conditions. Patient service programs are expected to triple in size post-acquisition within the next three years. Product business aims for a standard growth rate of approximately 15% annually. EBITDA margins are expected to stabilize and improve from next year onwards as operational expenditures settle. The company is optimistic about scaling patient service programs significantly, viewing them as a key future growth driver. EPS showed a 37.9% growth o

Current/ Expected Orderbook/ Pending Orders?

Current corporates provide enough scope for orders within pharma divisions, with around 30 divisions per company acting like separate companies. There is significant demand in the existing market plus new opportunities in insurance and other sectors. The existing order flow is sufficient to keep operations running full-scale. The company is increasing field technicians and dietitians to meet growing demand, conducting about 100 camps daily across 78 cities. An acquisition is underway expected to bring in additional order volume, roughly doubling patient services revenue from INR15-20 crores to

QMS MedicalQ3 FY24Healthcare Equipment & Supplies

QMS Medical Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹196P/E: 35.4Market Cap: ₹380 CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

The company aims to grow its patient service programs to INR 100 crores over the next three years, up from current INR 15-20 crores annually.
Growth includes acquisition of a similar-sized company expected to double the patient services segment.
Product business is targeted to grow at a steady rate of approximately 15% annually.
Focus on expanding the number of field technicians and dietitians to meet growing demand in patient services.
Online sales to increase gradually by expanding product portfolio beyond current limited range, focusing on wellness and fitness sectors.
The company plans to scale monthly revenues of own brands and patient services, aiming to double current monthly revenues in about a year.
Emphasis on sustainable EBITDA margins through higher-margin patient service camps and direct import of products.
Overall, the company is bullish on patient service programs and QDevices brand growth over the next 2-3 years.

Margin guidance

Category 3

The company focuses on achieving steady growth over the next 2-3 years rather than projecting long-term 5-year targets due to dynamic business conditions.
Patient service programs are expected to triple in size post-acquisition within the next three years.
Product business aims for a standard growth rate of approximately 15% annually.
EBITDA margins are expected to stabilize and improve from next year onwards as operational expenditures settle.
The company is optimistic about scaling patient service programs significantly, viewing them as a key future growth driver.
EPS showed a 37.9% growth over 9-month FY24 compared to the previous year, reflecting positive financial management and strategic initiatives.
No specific 5-year revenue or profit targets were outlined; focus remains on 2-3 year projections with ongoing revisions based on market conditions.

See what QMS Medical management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company is currently undertaking a preferential allotment (equity fundraising) to acquire a patient service programs company.
Due diligence and discussions regarding this acquisition are ongoing, with the announcement expected soon, possibly within the current quarter.
The funds raised through the preferential allotment will be used primarily for this acquisition.
For expanding the QDevices brand, capital is expected to come from existing revenue streams, not requiring additional capital raise.
There is no explicit mention of new debt fundraising in the provided excerpts.
The company focuses on growing both patient service programs and product business organically along with acquisitions funded through equity.

Order book

Current corporates provide enough scope for orders within pharma divisions, with around 30 divisions per company acting like separate companies.
There is significant demand in the existing market plus new opportunities in insurance and other sectors.
The existing order flow is sufficient to keep operations running full-scale.
The company is increasing field technicians and dietitians to meet growing demand, conducting about 100 camps daily across 78 cities.
An acquisition is underway expected to bring in additional order volume, roughly doubling patient services revenue from INR15-20 crores to INR100 crores in three years.
The business model receives bookings via an app from corporate clients which schedule camps at various doctor clinics.
Overall, order inflow and orderbook look healthy with a mix of existing corporate expansions and new business segments.

See what QMS Medical management said on order book — free account, 30 seconds.

Capex plans

Yes

The company has invested approximately INR 15 to 20 crores as capex, primarily towards equipment for Patient Service Camps. Each representative carries machinery worth INR 15 to 17 lakhs.
A significant capex has been brought in for the cancer model as part of new product efforts.
The focus is on increasing the number of technicians and field staff with devices over the next six to eight months to meet high demand.
Capital expenditures also support expansion in patient service programs and product business growth.
The company is pursuing acquisitions in the patient services business; due diligence is ongoing with announcements expected in the current quarter.
Strategic import of products under their own registration from CDSO has begun, to improve margins and reduce dependency on local vendors.
Efforts include expansion of the QDevices brand, increasing online presence, and adding wellness and fitness products.

Track QMS Medical — get its next earnings analysis in your feed

How does QMS Medical rank vs peers in Healthcare Equipment & Supplies?

Pro feature

ThisQMS Medical

Rev 2Mar 3

See where QMS Medical sits in Healthcare Equipment & SuppliesSee which companies these are, and every other name in the sector.Open rankings

How does QMS Medical rank in Healthcare Equipment & Supplies?

Compare QMS Medical against every Healthcare Equipment & Supplies company (Q3 FY24) on revenue, margins and earnings-call signals.

View Healthcare Equipment & Supplies leaderboard →

What QMS Medical's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

Fischer Medical Ventures Ltd (Q2 FY25)
EBITDA: ₹36.3 crore, a 45.5% year-on-year increase. Key concall takeaways from Fischer Medical Ventures Ltd's Q2 FY25 earnings call — and how it ranks against…
Fischer Medical Ventures Ltd (Q1 FY27)
The provided pages of the investor presentation do not contain any specific revenue, sales, or volume figures for the quarter, nor details on year-on-year…
OSEL Devices Ltd (Q1 FY26)
FY25 total income (revenue) was ₹18,660.07 lakhs, up 41% YoY from ₹13,268.52 lakhs in FY24. Key concall takeaways from OSEL Devices Ltd's Q1 FY26 earnings call…
Q-Line Biotech Ltd (Q4 FY26)
Shift towards more manufacturing with gross margins of 60-65% for reagents supporting profitability improvement (Page 7, 6). Key concall takeaways from Q-Line…

Compare:vs Poly Medicure Ltd vs Molbio Diagnosti vs Fischer Medical Ventures Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →